DrugDashboards

Bleomycin

Bleomycin · BLEOMYCIN SULFATE 15 [USP'U]/1 · Injection, Powder, Lyophilized, For Solution · Intramuscular; Intrapleural; Intravenous; Subcutaneous · Hospira, Inc.

NDC 00409-0332-20 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is down 17% over the past year, to $26.45 per unit. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$26.45per EAinvoice-surveyed acquisition cost · Apr 22, 2026
  • Medicare Part B pays (ASP+6%)$24.84per billing unit (15 UNITS)HCPCS J9040 · Jul 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$20.00$40.00Dec 2024Sep 2026$26.45
9 price points · per EA · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$25.73
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 15 UNITS
$24.838
HCPCS J9040 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2024)

$25
17 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 2 active manufacturers+20
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for bleomycin (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA065031
TE code
AP
Approval date
Mar 10, 2000
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Bleomycin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Hospira, Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 15 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BLEOMYCIN SULFATE 30 [USP'U]/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Bleomycin — NDC 00409-0332-20," retrieved September 3, 2026, https://drugdashboards.com/drug/00409033220.

Free to cite with attribution — see how the data is put together.